G6PD and non-autoimmune hemolytic anemia: The likelihood of developing haemolysis and its severity depends on the level of enzyme deficiency, which in turn is determined by the type of G6PD variant [16–18]. The risk for haemolytic anaemia is particularly high in patients who are treated for P. vivax malaria because they are usually given a higher dose of primaquine (0.25–0.5 mg in a 14-day treatment regime) compared to those treated for P. falciparum (a single dose of 0.25 mg on the first day of treatment) [19].